Drugs that target the PD-1 or PD-L1 axis have demonstrated durable tumor responses in 10–40% of patients in clinical trials including metastatic melanoma, renal cell carcinoma, nonsmall cell lung cancer, bladder cancer, triple-negative breast cancer (TNBC), and several other solid and hematological malignancies [24, 25]. The gene discussed is CD274; the disease is neoplasm.